Donald Halbert, Vishal Wanchoo, Eric Lander, Dorian Rinella, Alain Couder, Jussi Harvela, Jeffrey Duggan, Chris Capelli, David Goldstein | GenomeWeb

Donald Halbert this week was named executive vice president of research and development for Iconix Pharmaceuticals. Halbert was director of genomics, proteomics, and bioinformatics in the global pharmaceutical research and development group of Abbott Laboratories. Additionally, Halbert directed Abbott's toxicogenomics program and oversaw the scientific advisory committee that directed a collaboration between Abbott and Iconix that was initiated in December 2003. Before joining Abbott, Halbert was an executive with Becton Dickinson.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.